New year, new name, new bladder cancer data for Sesen Bio

New year, new name, new bladder cancer data for Sesen Bio  FierceBiotech Sesen Bio's lead ADC shows treatment effect in late-stage bladder cancer study  Seeking Alpha Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three ...  StockhouseFull coverage

Read More ...
New year, new name, new bladder cancer data for Sesen Bio published May 22, 2018 at 04:47AM. Original Source Link : https://www.fiercebiotech.com/biotech/new-year-new-name-new-bladder-cancer-data-for-sesen-bio

loading...